mstockstill on DSK4VPTVN1PROD with NOTICES


36550 Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices 

Parts Closed to the Public 

1. Procurement 

2. Security 

CONTACT PERSON FOR MORE INFORMATION: 

Kimberly Weaver, Director, Office of 

External Affairs, (202) 942–1640. 

Dated: June 13, 2013. 

James B. Petri, 

Secretary, Federal Retirement Thrift 

Investment Board. 

[FR Doc. 2013–14524 Filed 6–14–13; 11:15 am] 

BILLING CODE 6760–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Determination Concerning a Petition 

To Add a Class of Employees to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice of a 

determination concerning a petition to 

add a class of employees from the 

Brookhaven National Laboratory in 

Upton, New York, to the Special 

Exposure Cohort (SEC) under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000 

(EEOICPA). On June 7, 2013, the 

Secretary of HHS determined that the 

following class of employees does not 

meet the statutory criteria for addition 

to the SEC as authorized under 

EEOICPA: 

All employees of the Department of 

Energy, its predecessor agencies, and its 

contractors and subcontractors who worked 

at Brookhaven National Laboratory in Upton, 

New York, from January 1, 1994, to December 

31, 2007. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 1– 

877–222–7570. Information requests can 

also be submitted by email to 

DCAS@CDC.GOV. 

Dated: June 11, 2013. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2013–14389 Filed 6–17–13; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–13–13XA] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–7570 or send 

comments to Ron Otten, 1600 Clifton 

Road, MS–D74, Atlanta, GA 30333 or 

send an email to omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Improving HIV Prevention and 

Treatment Outcomes Among HIVInfected Persons by Integrating 

Community Pharmacists and Clinical 

Sites into a Model of Patient-Centered 

HIV Care—New—National Center for 

HIV/AIDS, Viral Hepatitis, STD and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Medication Therapy Management 

(MTM) is a group of pharmacist 

provided services that is independent 

of, but can occur in conjunction with, 

provision of medication. Medication 

Therapy Management encompasses a 

broad range of professional activities 

and cognitive services within the 

licensed pharmacists’ scope of practice 

and can include monitoring prescription 

filling patterns and timing of refills, 

checking for medication interactions, 

patient education, and monitoring of 

patient response to drug therapy. 

HIV specific MTM programs have 

demonstrated success in improving HIV 

medication therapy adherence and 

persistence. While MTM programs have 

be shown to be effective in increasing 

medication adherence for HIV-infected 

persons, no MTM programs have been 

expanded to incorporate primary 

medical providers in an effort to 

establish patient-centered HIV care. To 

address this problem CDC has entered 

into a public-private partnership with 

Walgreen Company (a.k.a Walgreens 

pharmacies, a national retail pharmacy 

chain) to develop and implement a 

model of HIV care that integrates 

community pharmacists with primary 

medical providers for patient-centered 

HIV care. The model program will be 

implemented in ten sites and will 

provide patient-centered HIV care for 

approximately 1,000 persons. 

The patient-centered HIV care model 

will include the core elements of MTM 

as well as additional services such as 

individualized medication adherence 

counseling, active monitoring of 

prescription refills and active 

collaboration between pharmacists and 

medical clinic providers to identify and 

resolve medication related treatment 

problems such as treatment 

effectiveness, adverse events and poor 

adherence. The expected outcomes of 

the model program are increased 

retention in HIV care, adherence to HIV 

medication therapy and viral load 

suppression. 

CDC requests OMB approval to collect 

standardized information, from ten 

project sites over the three year project 

period. CDC also requests approval to 

conduct one cycle of retrospective data 

collection during the first year of the 

three year project period. The 

retrospective data collection will 

provide information about clients’ 

baseline characteristics prior to 

participation in the model program 

which is needed to compare outcomes 

before and after program 

implementation. 

Pharmacy, laboratory and medical 

data will be collected through 

abstraction of all participant clients’ 

pharmacy and medical records. 

Pharmacy, laboratory and medical data 

are needed to monitor retention in care, 

adherence to therapy, viral load 

suppression and other health outcomes. 

Program specific data, such as the 

number of MTM elements completed 

per project site will be collected by 

program. Qualitative data will be 

gathered from program staff through inperson or telephone interviews.